Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) was upgraded by research analysts at TD Securities from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm currently has a C$25.50 price objective on the specialty pharmaceutical company’s stock. TD Securities’ price objective would indicate a potential upside of 34.71% from the company’s current price.

Separately, Royal Bank Of Canada lowered their price objective on Valeant Pharmaceuticals Intl to C$22.50 and set a “sector perform” rating for the company in a research note on Friday, October 20th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Valeant Pharmaceuticals Intl presently has an average rating of “Hold” and an average price target of C$22.50.

Shares of Valeant Pharmaceuticals Intl (TSE VRX) traded up C$0.84 during midday trading on Wednesday, reaching C$18.93. The company’s stock had a trading volume of 3,529,047 shares, compared to its average volume of 1,280,000. Valeant Pharmaceuticals Intl has a 12-month low of C$11.20 and a 12-month high of C$26.24.

TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals Intl Inc (VRX) Lifted to “Buy” at TD Securities” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at

In other news, Director Schutter Richard Urbain De bought 4,900 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was bought at an average price of C$14.35 per share, for a total transaction of C$70,315.00.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.